OBI Pharma (4174) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.132x

Based on the latest financial reports, OBI Pharma (4174) has a cash flow conversion efficiency ratio of -0.132x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-407.43 Million ≈ $-12.84 Million USD) by net assets (NT$3.08 Billion ≈ $97.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OBI Pharma (4174) defensive interval to measure how many days the company can operate on defensive assets alone.

OBI Pharma - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how OBI Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.

OBI Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of OBI Pharma ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Supercomnet Technologies Bhd KLSE:0001	0.025x
Gabelli Global Utility & Income Tr NYSE MKT:GLU	N/A
HyVision System. Inc KQ:126700	-0.033x
Stel Holdings Limited NSE:STEL	0.005x
INNATE PHARMA SP.ADR/1 F:IDDA	N/A
Leap Therapeutics Inc NASDAQ:LPTX	-6.045x
Norsk Titanium AS OL:NTI	-0.732x
Energoaqua a.s. PR:ENRGA	N/A

Annual Cash Flow Conversion Efficiency for OBI Pharma (2011–2024)

The table below shows the annual cash flow conversion efficiency of OBI Pharma from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market value of OBI Pharma.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$4.82 Billion ≈ $151.87 Million	NT$-1.83 Billion ≈ $-57.77 Million	-0.380x	-13.99%
2023-12-31	NT$4.95 Billion ≈ $156.06 Million	NT$-1.65 Billion ≈ $-52.08 Million	-0.334x	-26.42%
2022-12-31	NT$6.14 Billion ≈ $193.32 Million	NT$-1.62 Billion ≈ $-51.03 Million	-0.264x	+4.01%
2021-12-31	NT$3.87 Billion ≈ $121.95 Million	NT$-1.06 Billion ≈ $-33.54 Million	-0.275x	+17.34%
2020-12-31	NT$4.84 Billion ≈ $152.42 Million	NT$-1.61 Billion ≈ $-50.71 Million	-0.333x	-65.38%
2019-12-31	NT$5.20 Billion ≈ $163.96 Million	NT$-1.05 Billion ≈ $-32.98 Million	-0.201x	-4.12%
2018-12-31	NT$4.47 Billion ≈ $140.94 Million	NT$-864.31 Million ≈ $-27.23 Million	-0.193x	+11.67%
2017-12-31	NT$5.06 Billion ≈ $159.43 Million	NT$-1.11 Billion ≈ $-34.87 Million	-0.219x	-60.41%
2016-12-31	NT$6.16 Billion ≈ $194.10 Million	NT$-840.10 Million ≈ $-26.47 Million	-0.136x	-163.20%
2015-12-31	NT$7.18 Billion ≈ $226.34 Million	NT$-372.20 Million ≈ $-11.73 Million	-0.052x	+83.89%
2014-12-31	NT$1.44 Billion ≈ $45.49 Million	NT$-464.22 Million ≈ $-14.63 Million	-0.322x	-495.51%
2013-12-31	NT$1.93 Billion ≈ $60.78 Million	NT$-104.16 Million ≈ $-3.28 Million	-0.054x	+61.92%
2012-12-31	NT$829.77 Million ≈ $26.14 Million	NT$-117.64 Million ≈ $-3.71 Million	-0.142x	+85.82%
2011-12-31	NT$508.44 Million ≈ $16.02 Million	NT$-508.22 Million ≈ $-16.01 Million	-1.000x	--

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$116.20 Million

NT$3.69 Billion TWD

Market Cap Rank

#18718 Global

#1035 in Taiwan

Share Price

NT$28.05

Change (1 day)

+0.72%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00